Genetic Analysis AS (GA) has reported a robust performance for the second quarter of 2025, highlighting a 34% increase in sales from the corresponding period last year. This growth, driven by strong sales of GA-map® reagent kits in the US, has resulted in an operating income of NOK 7.2 million, up from NOK 5.0 million in Q2 2024.

The company has successfully launched the GA-map® Dysbiosis Test in the Chinese Consumer Health market, in collaboration with Thalys Medical Technology Group. This move marks GA's strategic entry into the rapidly growing Chinese microbiome diagnostic market, tapping into the potential of personalized health solutions.

Financially, GA has demonstrated significant improvements, with a positive EBITDA of NOK 0.5 million for the quarter, a stark contrast to the negative NOK 3.4 million in Q2 2024. The net loss has also narrowed considerably to NOK 1.0 million, compared to NOK 4.8 million in the previous year.

In addition, GA completed a directed share issue of NOK 12.8 million, primarily subscribed by existing shareholders, including Bio-Rad Laboratories. This capital raise is set to accelerate commercialization efforts and support ongoing collaborations, notably with Ferring Pharmaceuticals and Pangea Laboratory for the US launch of the GA-map® MHI GutHealth test.

With these positive developments and a strengthened board of directors, including the appointment of Morten Jurs and Ove Öhman, GA is well-positioned for future growth. The company’s strategic initiatives and financial resilience suggest a promising outlook, making it a compelling consideration for investors.

Given the current trajectory and strategic positioning of GA in the microbiome diagnostics sector, the recommendation is to hold the stock. The company’s ongoing innovations and market expansions are likely to yield further value in the coming quarters.